1. Show article details.

    BRIEF-Phasebio Launches Clinical Trial To Evaluate Pb1046 As A Treatment For Hospitalized Covid-19 Patients

    Reuters – 4:12 PM ET 05/27/2020

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO LAUNCHES CLINICAL TRIAL TO EVALUATE PB1046 AS A TREATMENT FOR HOSPITALIZED COVID-19 PATIENTS. * PHASEBIO PHARMA - RECEIVES CLEARANCE OF IND APPLICATION FROM U.S. FDA UNDER CORONAVIRUS TREATMENT ACCELERATION PROGRAM. * PHASEBIO PHARMACEUTICALS (PHAS) - TARGETING TO REPORT VANGARD TRIAL RESULTS LATE IN Q4 OF 2020.

  2. Show article details.

    PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

    Business Wire – 4:01 PM ET 05/27/2020

    PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome Based on FDA feedback, PhaseBio believes that positive, clearly interpretable and clinically meaningf...

  3. Show article details.

    BRIEF-PhaseBio Pharmaceuticals Q1 Loss Per Share $0.52

    Reuters – 4:18 PM ET 05/12/2020

    PhaseBio Pharmaceuticals Inc (PHAS): * PHASEBIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS. * Q1 LOSS PER SHARE $0.52. * Q1 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA. * INITIATED PB2452 PHASE 3 TRIAL FOR REVERSAL OF ANTIPLATELET EFFECTS OF TICAGRELOR.

  4. Show article details.

    PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

    Business Wire – 4:01 PM ET 05/12/2020

    Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.

  5. Show article details.

    PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

    GlobeNewswire – 8:01 AM ET 03/30/2020

    Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals® MALVERN, Pa. and SAN DIEGO, March 30, 2020 -- PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused ...

  6. Show article details.

    PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

    GlobeNewswire – 4:01 PM ET 02/26/2020

    PhaseBio Pharmaceuticals (PHAS), Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m. EST in Boston.

  7. Show article details.

    PhaseBio Appoints Alex C. Sapir to Board of Directors

    GlobeNewswire – 4:01 PM ET 02/13/2020

    PhaseBio Pharmaceuticals (PHAS), Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sapir to its board of directors.

  8. Show article details.

    PhaseBio Announces European Regulatory Update for PB2452

    GlobeNewswire – 8:00 AM ET 02/11/2020

    PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor MALVERN, Pa. and SAN DIEGO, Feb. 11, 2020 -- PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of nov...

  9. Show article details.

    PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress

    GlobeNewswire – 4:01 PM ET 02/04/2020

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a patient who received more than 18 months of treatment with PB1046, the company’s first-in-class, sustained-release vasoactive intestinal peptide analogue being evaluated for the tr...

  10. Show article details.

    PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

    GlobeNewswire – 4:01 PM ET 01/13/2020

    PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agreement with Viamet Pharmaceuticals Holdings, LLC and its wholly-owned subsidiary, Selenity Pharmaceuticals, Ltd., to acquire all of the assets and intellectual property rights related...

  11. Show article details.

    PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

    GlobeNewswire – 9:00 AM ET 01/10/2020

    PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support ...

Page:

Today's and Upcoming Events

  • Aug
    17

    PHAS to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    12

    PHAS announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.